The US Food and Drug Administration has approved Allergan’s Byvalson (nebivolol and valsartan) 5 mg/ 80 mg tablets for the treatment of hypertension to lower blood pressure.

Byvalson is a fixed-dose combination of a beta blocker and angiotensin II receptor blocker. Nebivolol (marketed in the US as Bystolic) is a beta-adrenergic receptor blocking agent that is preferentially beta-1 selective up to and including the 10 mg dose and in extensive metabolizers. Valsartan is an angiotensin II receptor blocker that blocks the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, thereby blocking its vasoconstrictor and aldosterone-secreting effects.

Source: Allergan